LIVE WEBINAR: Thursday, July 9, 2020, 5:00 PM – 6:00 PM ET

What Urologists Need to Know About Immune Checkpoint Inhibitors and Other Novel Approaches for Urothelial Bladder Cancer

A Live CME Webinar

Join us Thursday, July 9 for the live webinar
5:00 PM – 6:00 PM ET
1 AMA PRA Category 1 CreditTM

Complimentary Registration
A link to the event will be provided after registration via an email confirmation.

A full library of presentation slides will also be made available for those who participate in this live webinar.


Arjun Balar, MD
Associate Professor
Department of Medicine
Genitourinary Medical Oncology Program
NYU Perlmutter Cancer Center
New York, New York

Siamak Daneshmand, MD
Associate Professor of Urology (Clinical Scholar)
Director of Urologic Oncology
Director of Clinical Research
Urologic Oncology Fellowship Director
USC/Norris Comprehensive Cancer Center
Institute of Urology
Los Angeles, California

Ashish M Kamat, MD, MBBS
Professor of Urologic Oncology (Surgery)
Wayne B Duddlesten Professor of Cancer Research
Department of Urology, Division of Surgery
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Jonathan E Rosenberg, MD
Chief, Genitourinary Medical Oncology Service
Division of Solid Tumor Oncology
Enno W Ercklentz Chair
Memorial Sloan Kettering Cancer Center
New York, New York

Neil Love, MD
Research To Practice
Miami, Florida

Topics to be discussed:

Module 1: Integrating Immune Checkpoint Inhibitors into the Current Treatment Paradigm for Non-Muscle-Invasive Bladder Cancer

Module 2: Available Data with and Ongoing Investigation of Immune Checkpoint Inhibitors as Neoadjuvant and Adjuvant Therapy for Muscle-Invasive Bladder Cancer)

Module 3: Optimal Application of Immune Checkpoint Inhibitors in Therapy for Advanced Urothelial Bladder Carcinoma (UBC)

Module 4: Role of Recently FDA-Approved Therapies in the Management of Progressive UBC

Target Audience
This activity is intended for hematologists, medical oncologists, urologists and other healthcare providers involved in the treatment of urothelial bladder carcinoma.

Learning Objectives
At the conclusion of this activity, participants should be able to:

  • Analyze the biologic basis for the evaluation of immune checkpoint inhibitors in the management of urothelial bladder carcinoma (UBC).
  • Consider the recent FDA approval of pembrolizumab for patients with BCG-unresponsive, high-risk, non-muscle-invasive bladder cancer with carcinoma in situ with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy, and effectively identify individuals appropriate for this novel treatment approach.
  • Evaluate available and emerging data and ongoing research investigating the use of anti-PD-1/PD-L1 antibodies as neoadjuvant or adjuvant therapy for muscle-invasive bladder cancer, and refer eligible patients for appropriate trial participation.
  • Appreciate the FDA-approved indications for the various anti-PD-1/PD-L1 antibodies endorsed for the treatment of UBC in order to inform patients with advanced disease regarding the types and sequence of therapy they are likely to receive.
  • Review available and emerging clinical trial data evaluating the use of anti-PD-1/PD-L1 antibodies as maintenance therapy after or in combination with chemotherapy for patients with previously untreated metastatic UBC (mUBC), and consider the potential role of these approaches in routine practice.
  • Appraise available research data and ongoing clinical trials evaluating anti-PD-1/PD-L1 antibodies in combination with targeted agents or other immunotherapeutic strategies for mUBC, and counsel appropriately selected patients about participation in active research protocols.
  • Describe the frequency of fibroblast growth factor receptor (FGFR) abnormalities in patients with mUBC, and recognize the recent FDA approval of erdafitinib for mUBC with susceptible FGFR3 or FGFR2 alterations that has progressed during or after at least 1 line of platinum-containing chemotherapy.
  • Recall the pivotal clinical research findings supporting the recent FDA approval of enfortumab vedotin for previously treated mUBC, and identify patients for whom treatment with this novel compound may be appropriate.
  • Optimize appropriate and timely referral of patients with advanced presentations of UBC for medical oncology consultation regarding approved and emerging novel targeted and immunotherapeutic options.
  • Describe ongoing trials evaluating novel agents and strategies demonstrating promising activity in UBC, and counsel appropriately selected patients about availability and participation.

CME Credit Form
CME and ABIM MOC credit form links will be emailed to each participant within 5 days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Disclosure Policy
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

This activity is supported by educational grants from Astellas and Seattle Genetics and Merck.